Jeil Pharmaceutical Co.,Ltd
KSC: 271980.KS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Korea Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Seok-Jae Sung
- Employees
- 973
- Headquarters
- Seoul, South Korea
- IPO year
- 2017
- Market cap
- ₩199.9B
- Website
- https://www.jeilpharm.co.kr
Loading 271980…
Loading profile data…Frequently asked questions about 271980
What does Jeil Pharmaceutical Co.,Ltd (271980.KS) do?
Jeil Pharmaceutical Co.,Ltd develops and supplies pharmaceutical products primarily in South Korea. It provides products in the areas of antibiotic, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamine. The company also exports its products to approximately 40 countries in ASEAN, Centr...
Where does 271980.KS trade?
Jeil Pharmaceutical Co.,Ltd (271980.KS) trades on the Korea Exchange.
What sector is 271980.KS in?
Jeil Pharmaceutical Co.,Ltd (271980.KS) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Jeil Pharmaceutical Co.,Ltd?
Seok-Jae Sung is the chief executive officer of Jeil Pharmaceutical Co.,Ltd (271980.KS).
Where is Jeil Pharmaceutical Co.,Ltd headquartered?
Jeil Pharmaceutical Co.,Ltd is headquartered in South Korea.
Does 271980.KS pay a dividend?
Yes — Jeil Pharmaceutical Co.,Ltd (271980.KS) paid a trailing twelve-month dividend of KRW 50.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 271980.KS go public?
Jeil Pharmaceutical Co.,Ltd (271980.KS) completed its initial public offering in 2017.